Neuropeptide substance P and the immune response

Cellular and Molecular Life Sciences

Volumn 73, Issue 22, 2016, Pages 4249-4264

  Mashaghi, Alireza ^a   Marmalidou, Anna ^a   Tehrani, Mohsen ^a   Grace, Peter M ^b   Pothoulakis, Charalabos ^c   Dana, Reza ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cell to cell communication; Cellular dynamics; Immune regulation; Neuropeptides; Signaling

Indexed keywords

BETA ARRESTIN; CD18 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CXCL2 CHEMOKINE; CYCLIC AMP; DIACYLGLYCEROL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INOSITOL TRISPHOSPHATE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROKININ 1 RECEPTOR; NEUROKININ 2 RECEPTOR; NEUROKININ 2 RECEPTOR F; NEUROKININ 2 RECEPTOR T; NEUROKININ 3 RECEPTOR; RAB PROTEIN; RANTES; STEM CELL FACTOR; SUBSTANCE P; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ADAPTIVE IMMUNITY; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; EYE DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE; NONHUMAN; PLASMA HALF LIFE; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; UBIQUITINATION; UPREGULATION; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DISEASES; IMMUNITY; METABOLISM;

AMINO ACID SEQUENCE; ANIMALS; DISEASE; HUMANS; IMMUNITY; IMMUNOMODULATION; SIGNAL TRANSDUCTION; SUBSTANCE P;

EID: 84975142533     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-016-2293-z     Document Type: Review

References (253)

1. Us VE, Gaddum JH (1931) An unidentified depressor substance in certain tissue extracts. J Physiol 72:74–87
2. Chang MM, Leeman SE (1970) Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P. J Biol Chem 245:4784–4790
3. Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V (2002) The tachykinin peptide family. Pharmacol Rev 54:285–322
4. Krause JE, Chirgwin JM, Carter MS, Xu ZS, Hershey AD (1987) Three rat preprotachykinin mRNAs encode the neuropeptides substance P and neurokinin A. Proc Natl Acad Sci USA 84:881–885
5. Nawa H, Hirose T, Takashima H, Inayama S, Nakanishi S (1983) Nucleotide sequences of cloned cDNAs for two types of bovine brain substance P precursor. Nature 306:32–36
6. Ansel JC, Kaynard AH, Armstrong CA, Olerud J, Bunnett N, Payan D (1996) Skin–nervous system interactions. J Invest Dermatol 106:198–204
7. Hokfelt T, Johansson O, Ljungdahl A, Lundberg JM, Schultzberg M (1980) Peptidergic neurones. Nature 284:515–521
8. Holzer P (1988) Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience 24:739–768
9. Pickel VM, Reis DJ, Leeman SE (1977) Ultrastructural localization of substance P in neurons of rat spinal cord. Brain Res 122:534–540
10. Barker R, Larner A (1992) Substance P and multiple sclerosis. Med Hypotheses 37:40–43
11. Michel JP, Sakamoto N, Bouvier R, Tommasi M, Pearson J (1986) Substance P-immunoreactive astrocytes related to deep white matter and striatal blood vessels in human brain. Brain Res 377:383–387
12. Lai JP, Zhan GX, Campbell DE, Douglas SD, Ho WZ (2000) Detection of substance P and its receptor in human fetal microglia. Neuroscience 101:1137–1144
13. Watanabe M, Nakayasu K, Iwatsu M, Kanai A (2002) Endogenous substance P in corneal epithelial cells and keratocytes. Jpn J Ophthalmol 46:616–620
14. Milner P, Bodin P, Guiducci S, Del Rosso A, Kahaleh MB, Matucci-Cerinic M, Burnstock G (2004) Regulation of substance P mRNA expression in human dermal microvascular endothelial cells. Clin Exp Rheumatol 22:S24–S27
15. Lai JP, Douglas SD, Ho WZ (1998) Human lymphocytes express substance P and its receptor. J Neuroimmunol 86:80–86
16. Ho WZ, Lai JP, Zhu XH, Uvaydova M, Douglas SD (1997) Human monocytes and macrophages express substance P and neurokinin-1 receptor. J Immunol 159:5654–5660
17. Marriott I, Bost KL (2000) IL-4 and IFN-gamma up-regulate substance P receptor expression in murine peritoneal macrophages. J Immunol 165:182–191
18. Lambrecht BN, Germonpre PR, Everaert EG, Carro-Muino I, De Veerman M, de Felipe C, Hunt SP, Thielemans K, Joos GF, Pauwels RA (1999) Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation. Eur J Immunol 29:3815–3825
19. Weinstock JV, Blum A, Walder J, Walder R (1988) Eosinophils from granulomas in murine schistosomiasis mansoni produce substance P. J Immunol 141:961–966
20. Metwali A, Blum AM, Ferraris L, Klein JS, Fiocchi C, Weinstock JV (1994) Eosinophils within the healthy or inflamed human intestine produce substance P and vasoactive intestinal peptide. J Neuroimmunol 52:69–78
21. Li Y, Douglas SD, Ho W (2000) Human stem cells express substance P gene and its receptor. J Hematother Stem Cell Res 9:445–452
22. Cho KJ, Trzaska KA, Greco SJ, McArdle J, Wang FS, Ye JH, Rameshwar P (2005) Neurons derived from human mesenchymal stem cells show synaptic transmission and can be induced to produce the neurotransmitter substance P by interleukin-1 alpha. Stem Cells 23:383–391
23. Chang MM, Leeman SE, Niall HD (1971) Amino-acid sequence of substance P. Nat New Biol 232:86–87
24. McGregor GP, Bloom SR (1983) Radioimmunoassay of substance P and its stability in tissue. Life Sci 32:655–662
25. Rameshwar P, Joshi DD, Yadav P, Qian J, Gascon P, Chang VT, Anjaria D, Harrison JS, Song X (2001) Mimicry between neurokinin-1 and fibronectin may explain the transport and stability of increased substance P immunoreactivity in patients with bone marrow fibrosis. Blood 97:3025–3031
26. Skidgel RA, Engelbrecht S, Johnson AR, Erdos EG (1984) Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase. Peptides 5:769–776
27. Monastyrskaya K, Hostettler A, Buergi S, Draeger A (2005) The NK1 receptor localizes to the plasma membrane microdomains, and its activation is dependent on lipid raft integrity. J Biol Chem 280:7135–7146
28. Fong TM, Anderson SA, Yu H, Huang RR, Strader CD (1992) Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor. Mol Pharmacol 41:24–30
29. Lai JP, Ho WZ, Kilpatrick LE, Wang X, Tuluc F, Korchak HM, Douglas SD (2006) Full-length and truncated neurokinin-1 receptor expression and function during monocyte/macrophage differentiation. Proc Natl Acad Sci USA 103:7771–7776
30. Lai JP, Lai S, Tuluc F, Tansky MF, Kilpatrick LE, Leeman SE, Douglas SD (2008) Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor. Proc Natl Acad Sci USA 105:12605–12610
31. Caberlotto L, Hurd YL, Murdock P, Wahlin JP, Melotto S, Corsi M, Carletti R (2003) Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain. Eur J Neurosci 17:1736–1746
32. Marshall GE, Shehab SA, Spike RC, Todd AJ (1996) Neurokinin-1 receptors on lumbar spinothalamic neurons in the rat. Neuroscience 72:255–263
33. Todd AJ, McGill MM, Shehab SA (2000) Neurokinin 1 receptor expression by neurons in laminae I, III and IV of the rat spinal dorsal horn that project to the brainstem. Eur J Neurosci 12:689–700
34. Bockmann S (2002) Substance P (NK(1)) receptor expression by human colonic epithelial cell line Caco-2. Peptides 23:1783–1791
35. Greeno EW, Mantyh P, Vercellotti GM, Moldow CF (1993) Functional neurokinin 1 receptors for substance P are expressed by human vascular endothelium. J Exp Med 177:1269–1276
36. Maghni K, Michoud MC, Alles M, Rubin A, Govindaraju V, Meloche C, Martin JG (2003) Airway smooth muscle cells express functional neurokinin-1 receptors and the nerve-derived preprotachykinin-a gene: regulation by passive sensitization. Am J Respir Cell Mol Biol 28:103–110
37. Liu JY, Hu JH, Zhu QG, Li FQ, Sun HJ (2006) Substance P receptor expression in human skin keratinocytes and fibroblasts. Br J Dermatol 155:657–662
38. Feistritzer C, Clausen J, Sturn DH, Djanani A, Gunsilius E, Wiedermann CJ, Kahler CM (2003) Natural killer cell functions mediated by the neuropeptide substance P. Regul Pept 116:119–126
39. Marriott I, Bost KL (2001) Expression of authentic substance P receptors in murine and human dendritic cells. J Neuroimmunol 114:131–141
40. Germonpre PR, Bullock GR, Lambrecht BN, Van De Velde V, Luyten WH, Joos GF, Pauwels RA (1999) Presence of substance P and neurokinin 1 receptors in human sputum macrophages and U-937 cells. Eur Respir J 14:776–782
41. Chauhan VS, Sterka DG Jr, Gray DL, Bost KL, Marriott I (2008) Neurogenic exacerbation of microglial and astrocyte responses to Neisseria meningitidis and Borrelia burgdorferi. J Immunol 180:8241–8249
42. van der Kleij HP, Ma D, Redegeld FA, Kraneveld AD, Nijkamp FP, Bienenstock J (2003) Functional expression of neurokinin 1 receptors on mast cells induced by IL-4 and stem cell factor. J Immunol 171:2074–2079
43. McConalogue K, Corvera CU, Gamp PD, Grady EF, Bunnett NW (1998) Desensitization of the neurokinin-1 receptor (NK1-R) in neurons: effects of substance P on the distribution of NK1-R, Galphaq/11, G-protein receptor kinase-2/3, and beta-arrestin-1/2. Mol Biol Cell 9:2305–2324
44. Grady EF, Garland AM, Gamp PD, Lovett M, Payan DG, Bunnett NW (1995) Delineation of the endocytic pathway of substance P and its seven-transmembrane domain NK1 receptor. Mol Biol Cell 6:509–524
45. Nishimura K, Warabi K, Roush ED, Frederick J, Schwinn DA, Kwatra MM (1998) Characterization of GRK2-catalyzed phosphorylation of the human substance P receptor in Sf9 membranes. Biochemistry 37:1192–1198
46. McConalogue K, Dery O, Lovett M, Wong H, Walsh JH, Grady EF, Bunnett NW (1999) Substance P-induced trafficking of beta-arrestins. The role of beta-arrestins in endocytosis of the neurokinin-1 receptor. J Biol Chem 274:16257–16268
47. Roosterman D, Cottrell GS, Schmidlin F, Steinhoff M, Bunnett NW (2004) Recycling and resensitization of the neurokinin 1 receptor. Influence of agonist concentration and Rab GTPases. J Biol Chem 279:30670–30679
48. Vigna SR (1999) Phosphorylation and desensitization of neurokinin-1 receptor expressed in epithelial cells. J Neurochem 73:1925–1932
49. Beinborn M, Blum A, Hang L, Setiawan T, Schroeder JC, Stoyanoff K, Leung J, Weinstock JV (2010) TGF-beta regulates T-cell neurokinin-1 receptor internalization and function. Proc Natl Acad Sci USA 107:4293–4298
50. Blum AM, Metwali A, Crawford C, Li J, Qadir K, Elliott DE, Weinstock JV (2001) Interleukin 12 and antigen independently induce substance P receptor expression in T cells in murine schistosomiasis mansoni. FASEB J 15:950–957
51. Weinstock JV, Blum A, Metwali A, Elliott D, Arsenescu R (2003) IL-18 and IL-12 signal through the NF-kappa B pathway to induce NK1R expression on T cells. J Immunol 170:5003–5007
52. Pelayo JC, Poole DP, Steinhoff M, Cottrell GS, Bunnett NW (2011) Endothelin-converting enzyme-1 regulates trafficking and signalling of the neurokinin 1 receptor in endosomes of myenteric neurones. J Physiol 589:5213–5230
53. Whyteside AR, Turner AJ, Lambert DW (2014) Endothelin-converting enzyme-1 (ECE-1) is post-transcriptionally regulated by alternative polyadenylation. PLoS One 9:e83260
54. Lo SY, Brett CL, Plemel RL, Vignali M, Fields S, Gonen T, Merz AJ (2012) Intrinsic tethering activity of endosomal Rab proteins. Nat Struct Mol Biol 19:40–47
55. Mukherjee S, Liu X, Arasaki K, McDonough J, Galan JE, Roy CR (2011) Modulation of Rab GTPase function by a protein phosphocholine transferase. Nature 477:103–106
56. Tuluc F, Meshki J, Spitsin S, Douglas SD (2014) HIV infection of macrophages is enhanced in the presence of increased expression of CD163 induced by substance P. J Leukoc Biol 96:143–150
57. Murphy JE, Roosterman D, Cottrell GS, Padilla BE, Feld M, Brand E, Cedron WJ, Bunnett NW, Steinhoff M (2011) Protein phosphatase 2A mediates resensitization of the neurokinin 1 receptor. Am J Physiol Cell Physiol 301:C780–C791
58. Christian C, Gilbert M, Payan DG (1994) Stimulation of transcriptional regulatory activity by substance P. Neuroimmunomodulation 1:159–164
59. Derocq JM, Segui M, Blazy C, Emonds-Alt X, Le Fur G, Brelire JC, Casellas P (1996) Effect of substance P on cytokine production by human astrocytic cells and blood mononuclear cells: characterization of novel tachykinin receptor antagonists. FEBS Lett 399:321–325
60. Fiebich BL, Schleicher S, Butcher RD, Craig A, Lieb K (2000) The neuropeptide substance P activates p38 mitogen-activated protein kinase resulting in IL-6 expression independently from NF-kappa B. J Immunol 165:5606–5611
61. Foldenauer ME, McClellan SA, Berger EA, Hazlett LD (2013) Mammalian target of rapamycin regulates IL-10 and resistance to Pseudomonas aeruginosa corneal infection. J Immunol 190:5649–5658
62. Guo CJ, Lai JP, Luo HM, Douglas SD, Ho WZ (2002) Substance P up-regulates macrophage inflammatory protein-1beta expression in human T lymphocytes. J Neuroimmunol 131:160–167
63. Koizumi H, Yasui C, Fukaya T, Ueda T, Ohkawara A (1994) Substance P induces inositol 1,4,5-trisphosphate and intracellular free calcium increase in cultured normal human epidermal keratinocytes. Exp Dermatol 3:40–44
64. Koon HW, Zhao D, Zhan Y, Simeonidis S, Moyer MP, Pothoulakis C (2005) Substance P-stimulated interleukin-8 expression in human colonic epithelial cells involves protein kinase C delta activation. J Pharmacol Exp Ther 314:1393–1400
65. Lieb K, Fiebich BL, Berger M, Bauer J, Schulze-Osthoff K (1997) The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. J Immunol 159:4952–4958
66. Quinlan KL, Naik SM, Cannon G, Armstrong CA, Bunnett NW, Ansel JC, Caughman SW (1999) Substance P activates coincident NF-AT- and NF-kappa B-dependent adhesion molecule gene expression in microvascular endothelial cells through intracellular calcium mobilization. J Immunol 163:5656–5665
67. Sun J, Ramnath RD, Zhi L, Tamizhselvi R, Bhatia M (2008) Substance P enhances NF-kappaB transactivation and chemokine response in murine macrophages via ERK1/2 and p38 MAPK signaling pathways. Am J Physiol Cell Physiol 294:C1586–C1596
68. Zhao D, Kuhnt-Moore S, Zeng H, Pan A, Wu JS, Simeonidis S, Moyer MP, Pothoulakis C (2002) Substance P-stimulated interleukin-8 expression in human colonic epithelial cells involves Rho family small GTPases. Biochem J 368:665–672
69. Cao YQ, Mantyh PW, Carlson EJ, Gillespie AM, Epstein CJ, Basbaum AI (1998) Primary afferent tachykinins are required to experience moderate to intense pain. Nature 392:390–394
70. De Felipe C, Herrero JF, O’Brien JA, Palmer JA, Doyle CA, Smith AJ, Laird JM, Belmonte C, Cervero F, Hunt SP (1998) Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 392:394–397
71. Lembeck F, Holzer P (1979) Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch Pharmacol 310:175–183
72. Xanthos DN, Sandkuhler J (2014) Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. Nat Rev Neurosci 15:43–53
73. Nilsson J, von Euler AM, Dalsgaard CJ (1985) Stimulation of connective tissue cell growth by substance P and substance K. Nature 315:61–63
74. Payan DG (1985) Receptor-mediated mitogenic effects of substance P on cultured smooth muscle cells. Biochem Biophys Res Commun 130:104–109
75. Lotz M, Carson DA, Vaughan JH (1987) Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science 235:893–895
76. Cury PR, Canavez F, de Araujo VC, Furuse C, de Araujo NS (2008) Substance P regulates the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in cultured human gingival fibroblasts. J Periodontal Res 43:255–260
77. Bull HA, Hothersall J, Chowdhury N, Cohen J, Dowd PM (1996) Neuropeptides induce release of nitric oxide from human dermal microvascular endothelial cells. J Invest Dermatol 106:655–660
78. Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, Geppetti P, Ledda F (1994) Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 94:2036–2044
79. Ziche M, Morbidelli L, Pacini M, Geppetti P, Alessandri G, Maggi CA (1990) Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res 40:264–278
80. Liu D, Jiang LS, Dai LY (2007) Substance P and its receptors in bone metabolism. Neuropeptides 41:271–283
81. Castagliuolo I, Valenick L, Liu J, Pothoulakis C (2000) Epidermal growth factor receptor transactivation mediates substance P-induced mitogenic responses in U-373 MG cells. J Biol Chem 275:26545–26550
82. Luo W, Sharif TR, Sharif M (1996) Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res 56:4983–4991
83. O’Connor TM, O’Connell J, O’Brien DI, Goode T, Bredin CP, Shanahan F (2004) The role of substance P in inflammatory disease. J Cell Physiol 201:167–180
84. Pavlova MN, Kaz’min AI, Abal’masova EA, Barer FS (1976) Pathomorphological characteristics of the intervertebral disks in scoliosis of varying etiology. Ortop Travmatol Prot 1–7
85. Weinstock JV (2015) Substance P and the regulation of inflammation in infections and inflammatory bowel disease. Acta Physiol 213:453–461
86. Taracanova A, Theoharides T (2015) Substance P and IL-33 synergistically stimulate mast cells to release IL-1β and TNF-α implicated in psoriasis; inhibition by the flavonoid methoxyluteolin. FASEB J 29
87. Vilisaar J, Kawabe K, Braitch M, Aram J, Furtun Y, Fahey AJ, Chopra M, Tanasescu R, Tighe PJ, Gran B, Pothoulakis C, Constantinescu CS (2015) Reciprocal regulation of substance P and IL-12/IL-23 and the associated cytokines, IFNgamma/IL-17: a perspective on the relevance of this interaction to multiple sclerosis. J Neuroimmune Pharmacol 10:457–467
88. Kimbrell DA, Beutler B (2001) The evolution and genetics of innate immunity. Nat Rev Genet 2:256–267
89. Gasteiger G, Rudensky AY (2014) Interactions between innate and adaptive lymphocytes. Nat Rev Immunol 14:631–639
90. Iwasaki A, Medzhitov R (2015) Control of adaptive immunity by the innate immune system. Nat Immunol 16:343–353
91. Jeon HK, Jung NP, Choi IH, Oh YK, Shin HC, Gwag BJ (1999) Substance P augments nitric oxide production and gene expression in murine macrophages. Immunopharmacology 41:219–226
92. Kavelaars A, Broeke D, Jeurissen F, Kardux J, Meijer A, Franklin R, Gelfand EW, Heijnen CJ (1994) Activation of human monocytes via a non-neurokinin substance P receptor that is coupled to Gi protein, calcium, phospholipase D, MAP kinase, and IL-6 production. J Immunol 153:3691–3699
93. Voedisch S, Rochlitzer S, Veres TZ, Spies E, Braun A (2012) Neuropeptides control the dynamic behavior of airway mucosal dendritic cells. PLoS One 7:e45951
94. Janelsins BM, Mathers AR, Tkacheva OA, Erdos G, Shufesky WJ, Morelli AE, Larregina AT (2009) Proinflammatory tachykinins that signal through the neurokinin 1 receptor promote survival of dendritic cells and potent cellular immunity. Blood 113:3017–3026
95. Janelsins BM, Sumpter TL, Tkacheva OA, Rojas-Canales DM, Erdos G, Mathers AR, Shufesky WJ, Storkus WJ, Falo LD Jr, Morelli AE, Larregina AT (2013) Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12. Blood 121:2923–2933
96. Takashima A (2013) Harnessing DCs by substance P. Blood 121:2815–2816
97. Barros PO, Ferreira TB, Vieira MM, Almeida CR, Araujo-Lima CF, Silva-Filho RG, Hygino J, Andrade RM, Andrade AF, Bento CA (2011) Substance P enhances Th17 phenotype in individuals with generalized anxiety disorder: an event resistant to glucocorticoid inhibition. J Clin Immunol 31:51–59
98. Cunin P, Caillon A, Corvaisier M, Garo E, Scotet M, Blanchard S, Delneste Y, Jeannin P (2011) The tachykinins substance P and hemokinin-1 favor the generation of human memory Th17 cells by inducing IL-1beta, IL-23, and TNF-like 1A expression by monocytes. J Immunol 186:4175–4182
99. Sun J, Ramnath RD, Tamizhselvi R, Bhatia M (2008) Neurokinin A engages neurokinin-1 receptor to induce NF-kappaB-dependent gene expression in murine macrophages: implications of ERK1/2 and PI 3-kinase/Akt pathways. Am J Physiol Cell Physiol 295:C679–C691
100. Kitamura H, Kobayashi M, Wakita D, Nishimura T (2012) Neuropeptide signaling activates dendritic cell-mediated type 1 immune responses through neurokinin-2 receptor. J Immunol 188:4200–4208
101. Asahina A, Hosoi J, Murphy GF, Granstein RD (1995) Calcitonin gene-related peptide modulates Langerhans cell antigen-presenting function. Proc Assoc Am Physicians 107:242–244
102. Carucci JA, Ignatius R, Wei Y, Cypess AM, Schaer DA, Pope M, Steinman RM, Mojsov S (2000) Calcitonin gene-related peptide decreases expression of HLA-DR and CD86 by human dendritic cells and dampens dendritic cell-driven T cell-proliferative responses via the type I calcitonin gene-related peptide receptor. J Immunol 164:3494–3499
103. Fox FE, Kubin M, Cassin M, Niu Z, Hosoi J, Torii H, Granstein RD, Trinchieri G, Rook AH (1997) Calcitonin gene-related peptide inhibits proliferation and antigen presentation by human peripheral blood mononuclear cells: effects on B7, interleukin 10, and interleukin 12. J Invest Dermatol 108:43–48
104. Hosoi J, Murphy GF, Egan CL, Lerner EA, Grabbe S, Asahina A, Granstein RD (1993) Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide. Nature 363:159–163
105. Mikami N, Matsushita H, Kato T, Kawasaki R, Sawazaki T, Kishimoto T, Ogitani Y, Watanabe K, Miyagi Y, Sueda K, Fukada S, Yamamoto H, Tsujikawa K (2011) Calcitonin gene-related peptide is an important regulator of cutaneous immunity: effect on dendritic cell and T cell functions. J Immunol 186:6886–6893
106. Nong YH, Titus RG, Ribeiro JM, Remold HG (1989) Peptides encoded by the calcitonin gene inhibit macrophage function. J Immunol 143:45–49
107. Rochlitzer S, Veres TZ, Kuhne K, Prenzler F, Pilzner C, Knothe S, Winkler C, Lauenstein HD, Willart M, Hammad H, Muller M, Krug N, Lambrecht BN, Braun A (2011) The neuropeptide calcitonin gene-related peptide affects allergic airway inflammation by modulating dendritic cell function. Clin Exp Allergy 41:1609–1621
108. Asahina A, Hosoi J, Beissert S, Stratigos A, Granstein RD (1995) Inhibition of the induction of delayed-type and contact hypersensitivity by calcitonin gene-related peptide. J Immunol 154:3056–3061
109. Liu J, Chen M, Wang X (2000) Calcitonin gene-related peptide inhibits lipopolysaccharide-induced interleukin-12 release from mouse peritoneal macrophages, mediated by the cAMP pathway. Immunology 101:61–67
110. Mikami N, Sueda K, Ogitani Y, Otani I, Takatsuji M, Wada Y, Watanabe K, Yoshikawa R, Nishioka S, Hashimoto N, Miyagi Y, Fukada S, Yamamoto H, Tsujikawa K (2014) Calcitonin gene-related peptide regulates type IV hypersensitivity through dendritic cell functions. PLoS One 9:e86367
111. Ding W, Stohl LL, Wagner JA, Granstein RD (2008) Calcitonin gene-related peptide biases Langerhans cells toward Th2-type immunity. J Immunol 181:6020–6026
112. Mikami N, Watanabe K, Hashimoto N, Miyagi Y, Sueda K, Fukada S, Yamamoto H, Tsujikawa K (2012) Calcitonin gene-related peptide enhances experimental autoimmune encephalomyelitis by promoting Th17-cell functions. Int Immunol 24:681–691
113. Lipton JM, Catania A (1997) Anti-inflammatory actions of the neuroimmunomodulator alpha-MSH. Immunol Today 18:140–145
114. Luger TA, Scholzen TE, Brzoska T, Bohm M (2003) New insights into the functions of alpha-MSH and related peptides in the immune system. Ann N Y Acad Sci 994:133–140
115. Star RA, Rajora N, Huang J, Stock RC, Catania A, Lipton JM (1995) Evidence of autocrine modulation of macrophage nitric oxide synthase by alpha-melanocyte-stimulating hormone. Proc Natl Acad Sci USA 92:8016–8020
116. Taylor AW, Yee DG, Nishida T, Namba K (2000) Neuropeptide regulation of immunity. The immunosuppressive activity of alpha-melanocyte-stimulating hormone (alpha-MSH). Ann N Y Acad Sci 917:239–247
117. Namba K, Kitaichi N, Nishida T, Taylor AW (2002) Induction of regulatory T cells by the immunomodulating cytokines alpha-melanocyte-stimulating hormone and transforming growth factor-beta2. J Leukoc Biol 72:946–952
118. Taylor A, Namba K (2001) In vitro induction of CD25+ CD4+ regulatory T cells by the neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH). Immunol Cell Biol 79:358–367
119. Taylor AW (2003) Modulation of regulatory T cell immunity by the neuropeptide alpha-melanocyte stimulating hormone. Cell Mol Biol (Noisy-le-grand) 49:143–149
120. Delgado M, Gonzalez-Rey E, Ganea D (2005) The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J Immunol 175:7311–7324
121. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D (1999) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation. J Immunol 162:4685–4696
122. Delgado M, Reduta A, Sharma V, Ganea D (2004) VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells. J Leukoc Biol 75:1122–1130
123. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D (1999) VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J Neuroimmunol 96:167–181
124. Goetzl EJ, Voice JK, Shen S, Dorsam G, Kong Y, West KM, Morrison CF, Harmar AJ (2001) Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide. Proc Natl Acad Sci USA 98:13854–13859
125. Delgado M, Gonzalez-Rey E, Ganea D (2004) VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells. FASEB J 18:1453–1455
126. Delgado M, Leceta J, Ganea D (2002) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. FASEB J 16:1844–1846
127. Delgado M, Leceta J, Gomariz RP, Ganea D (1999) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression. J Immunol 163:3629–3635
128. Voice J, Donnelly S, Dorsam G, Dolganov G, Paul S, Goetzl EJ (2004) c-Maf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide. J Immunol 172:7289–7296
129. Delgado M, Chorny A, Gonzalez-Rey E, Ganea D (2005) Vasoactive intestinal peptide generates CD4+ CD25+ regulatory T cells in vivo. J Leukoc Biol 78:1327–1338
130. Gonzalez-Rey E, Chorny A, Fernandez-Martin A, Ganea D, Delgado M (2006) Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood 107:3632–3638
131. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado M (2006) Vasoactive intestinal peptide induces CD4+, CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis. Arthritis Rheum 54:864–876
132. Jimeno R, Leceta J, Garin M, Ortiz AM, Mellado M, Rodriguez-Frade JM, Martinez C, Perez-Garcia S, Gomariz RP, Juarranz Y (2015) Th17 polarization of memory Th cells in early arthritis: the vasoactive intestinal peptide effect. J Leukoc Biol 98:257–269
133. Yadav M, Goetzl EJ (2008) Vasoactive intestinal peptide-mediated Th17 differentiation: an expanding spectrum of vasoactive intestinal peptide effects in immunity and autoimmunity. Ann N Y Acad Sci 1144:83–89
134. Ahluwalia A, De Felipe C, O’Brien J, Hunt SP, Perretti M (1998) Impaired IL-1 beta-induced neutrophil accumulation in tachykinin NK1 receptor knockout mice. Br J Pharmacol 124:1013–1015
135. Castellani ML, Vecchiet J, Salini V, Conti P, Theoharides TC, Caraffa A, Antinolfi P, Tete S, Ciampoli C, Cuccurullo C, Cerulli G, Felaco M, Boscolo P (2009) Stimulation of CCL2 (MCP-1) and CCL2 mRNA by substance P in LAD2 human mast cells. Transl Res 154:27–33
136. Chernova I, Lai JP, Li H, Schwartz L, Tuluc F, Korchak HM, Douglas SD, Kilpatrick LE (2009) Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R). J Leukoc Biol 85:154–164
137. Tran MT, Lausch RN, Oakes JE (2000) Substance P differentially stimulates IL-8 synthesis in human corneal epithelial cells. Invest Ophthalmol Vis Sci 41:3871–3877
138. Serra MC, Calzetti F, Ceska M, Cassatella MA (1994) Effect of substance P on superoxide anion and IL-8 production by human PMNL. Immunology 82:63–69
139. Okayama Y, Ono Y, Nakazawa T, Church MK, Mori M (1998) Human skin mast cells produce TNF-alpha by substance P. Int Arch Allergy Immunol 117(Suppl 1):48–51
140. Huang GT, Lee HW, Lee HS, Lee GH, Huh SY, Choi GW, Park SH (2008) Localization of substance P-induced upregulated interleukin-8 expression in human dental pulp explants. Int Endod J 41:100–107
141. Forster R, Davalos-Misslitz AC, Rot A (2008) CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol 8:362–371
142. Mathers AR, Tckacheva OA, Janelsins BM, Shufesky WJ, Morelli AE, Larregina AT (2007) In vivo signaling through the neurokinin 1 receptor favors transgene expression by Langerhans cells and promotes the generation of Th1- and Tc1-biased immune responses. J Immunol 178:7006–7017
143. Matis WL, Lavker RM, Murphy GF (1990) Substance P induces the expression of an endothelial-leukocyte adhesion molecule by microvascular endothelium. J Invest Dermatol 94:492–495
144. Ren K, Dubner R (2010) Interactions between the immune and nervous systems in pain. Nat Med 16:1267–1276
145. Kan A, Hodgkin P (2014) Mechanisms of cell division as regulators of acute immune response. Syst Synth Biol 8:215–221
146. Mashaghi A, Dekker C (2014) Systems and synthetic biology approaches to cell division. Syst Synth Biol 8:173–178
147. Calvo CF, Chavanel G, Senik A (1992) Substance P enhances IL-2 expression in activated human T cells. J Immunol 148:3498–3504
148. Nio DA, Moylan RN, Roche JK (1993) Modulation of T lymphocyte function by neuropeptides. Evidence for their role as local immunoregulatory elements. J Immunol 150:5281–5288
149. Payan DG, Brewster DR, Goetzl EJ (1983) Specific stimulation of human T lymphocytes by substance P. J Immunol 131:1613–1615
150. Rameshwar P, Gascon P, Ganea D (1993) Stimulation of IL-2 production in murine lymphocytes by substance P and related tachykinins. J Immunol 151:2484–2496
151. Scicchitano R, Biennenstock J, Stanisz AM (1988) In vivo immunomodulation by the neuropeptide substance P. Immunology 63:733–735
152. Rameshwar P, Zhu G, Donnelly RJ, Qian J, Ge H, Goldstein KR, Denny TN, Gascon P (2001) The dynamics of bone marrow stromal cells in the proliferation of multipotent hematopoietic progenitors by substance P: an understanding of the effects of a neurotransmitter on the differentiating hematopoietic stem cell. J Neuroimmunol 121:22–31
153. Mei G, Xia L, Zhou J, Zhang Y, Tuo Y, Fu S, Zou Z, Wang Z, Jin D (2013) Neuropeptide SP activates the WNT signal transduction pathway and enhances the proliferation of bone marrow stromal stem cells. Cell Biol Int 37:1225–1232
154. Rameshwar P, Gascon P (1995) Substance P (SP) mediates production of stem cell factor and interleukin-1 in bone marrow stroma: potential autoregulatory role for these cytokines in SP receptor expression and induction. Blood 86:482–490
155. Hong HS, Lee J, Lee E, Kwon YS, Ahn W, Jiang MH, Kim JC, Son Y (2009) A new role of substance P as an injury-inducible messenger for mobilization of CD29(+) stromal-like cells. Nat Med 15:425–435
156. Shaik-Dasthagirisaheb YB, Varvara G, Murmura G, Saggini A, Potalivo G, Caraffa A, Antinolfi P, Tete S, Tripodi D, Conti F, Cianchetti E, Toniato E, Rosati M, Conti P, Speranza L, Pantalone A, Saggini R, Theoharides TC, Pandolfi F (2013) Vascular endothelial growth factor (VEGF), mast cells and inflammation. Int J Immunopathol Pharmacol 26:327–335
157. Katsanos GS, Anogeianaki A, Orso C, Tete S, Salini V, Antinolfi PL, Sabatino G (2008) Impact of substance P on cellular immunity. J Biol Regul Homeost Agents 22:93–98
158. Kohara H, Tajima S, Yamamoto M, Tabata Y (2010) Angiogenesis induced by controlled release of neuropeptide substance P. Biomaterials 31:8617–8625
159. Bignami F, Giacomini C, Lorusso A, Aramini A, Rama P, Ferrari G (2014) NK1 receptor antagonists as a new treatment for corneal neovascularization. Invest Ophthalmol Vis Sci 55:6783–6794
160. Weinstock JV, Blum A, Metwali A, Elliott D, Bunnett N, Arsenescu R (2003) Substance P regulates Th1-type colitis in IL-10 knockout mice. J Immunol 171:3762–3767
161. Simeonidis S, Castagliuolo I, Pan A, Liu J, Wang CC, Mykoniatis A, Pasha A, Valenick L, Sougioultzis S, Zhao D, Pothoulakis C (2003) Regulation of the NK-1 receptor gene expression in human macrophage cells via an NF-kappa B site on its promoter. Proc Natl Acad Sci USA 100:2957–2962
162. Fu WX, Qin B, Zhou AP, Yu QY, Huang QJ, Liang ZF (2011) Regulation of NK92-MI cell cytotoxicity by substance P. Scand J Immunol 74:107–113
163. 2+ concentration and inositol phosphate formation. J Immunol 141:2118–2124
164. Wozniak A, McLennan G, Betts WH, Murphy GA, Scicchitano R (1989) Activation of human neutrophils by substance P: effect on FMLP-stimulated oxidative and arachidonic acid metabolism and on antibody-dependent cell-mediated cytotoxicity. Immunology 68:359–364
165. Ottosson A, Edvinsson L (1997) Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia 17:166–174
166. Bar-Shavit Z, Goldman R, Stabinsky Y, Gottlieb P, Fridkin M, Teichberg VI, Blumberg S (1980) Enhancement of phagocytosis—a newly found activity of substance P residing in its N-terminal tetrapeptide sequence. Biochem Biophys Res Commun 94:1445–1451
167. Hartung HP, Toyka KV (1983) Activation of macrophages by substance P: induction of oxidative burst and thromboxane release. Eur J Pharmacol 89:301–305
168. Murris-Espin M, Pinelli E, Pipy B, Leophonte P, Didier A (1995) Substance P and alveolar macrophages: effects on oxidative metabolism and eicosanoid production. Allergy 50:334–339
169. Tancowny BP, Karpov V, Schleimer RP, Kulka M (2010) Substance P primes lipoteichoic acid- and Pam3CysSerLys4-mediated activation of human mast cells by up-regulating Toll-like receptor 2. Immunology 131:220–230
170. Asadi S, Alysandratos KD, Angelidou A, Miniati A, Sismanopoulos N, Vasiadi M, Zhang B, Kalogeromitros D, Theoharides TC (2012) Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells. J Invest Dermatol 132:324–329
171. Kroegel C, Giembycz MA, Barnes PJ (1990) Characterization of eosinophil cell activation by peptides. Differential effects of substance P, melittin, and FMET-Leu-Phe. J Immunol 145:2581–2587
172. Pascual DW, Xu-Amano JC, Kiyono H, McGhee JR, Bost KL (1991) Substance P acts directly upon cloned B lymphoma cells to enhance IgA and IgM production. J Immunol 146:2130–2136
173. Eglezos A, Andrews PV, Boyd RL, Helme RD (1990) Effects of capsaicin treatment on immunoglobulin secretion in the rat: further evidence for involvement of tachykinin-containing afferent nerves. J Neuroimmunol 26:131–138
174. Ikeda Y, Takei H, Matsumoto C, Mase A, Yamamoto M, Takeda S, Ishige A, Watanabe K (2007) Administration of substance P during a primary immune response amplifies the secondary immune response via a long-lasting effect on CD8+ T lymphocytes. Arch Dermatol Res 299:345–351
175. Jin Y, Hong HS, Son Y (2015) Substance P enhances mesenchymal stem cells-mediated immune modulation. Cytokine 71:145–153
176. Hazlett LD, McClellan SA, Barrett RP, Liu J, Zhang Y, Lighvani S (2007) Spantide I decreases type I cytokines, enhances IL-10, and reduces corneal perforation in susceptible mice after Pseudomonas aeruginosa infection. Invest Ophthalmol Vis Sci 48:797–807
177. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, Hale JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Carlson EJ, Hargreaves RJ, Rupniak NM (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281:1640–1645
178. Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D, Ghosh K, Ball WA, Reines SA, Munjack D, Apter JT, Cunningham L, Kling M, Bari M, Getson A, Lee Y (2004) Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 29:385–392
179. Munoz M, Rosso M (2010) The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs 28:187–193
180. Rupniak NM, Kramer MS (1999) Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci 20:485–490
181. Twardy BS, Channappanavar R, Suvas S (2011) Substance P in the corneal stroma regulates the severity of herpetic stromal keratitis lesions. Invest Ophthalmol Vis Sci 52:8604–8613
182. Rameshwar P, Ganea D, Gascon P (1994) Induction of IL-3 and granulocyte-macrophage colony-stimulating factor by substance P in bone marrow cells is partially mediated through the release of IL-1 and IL-6. J Immunol 152:4044–4054
183. Tebas P, Spitsin S, Barrett JS, Tuluc F, Elci O, Korelitz JJ, Wagner W, Winters A, Kim D, Catalano R, Evans DL, Douglas SD (2015) Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults. Aids 29:931–939
184. Keeble J, Blades M, Pitzalis C, Castro da Rocha FA, Brain SD (2005) The role of substance P in microvascular responses in murine joint inflammation. Br J Pharmacol 144:1059–1066
185. Knodell RG, Handwerger BS, Morley JE, Levine AS, Brown DM (1984) Separate influences of insulin and hyperglycemia on hepatic drug metabolism in mice with genetic and chemically induced diabetes mellitus. J Pharmacol Exp Ther 230:256–262
186. Razavi R, Chan Y, Afifiyan FN, Liu XJ, Wan X, Yantha J, Tsui H, Tang L, Tsai S, Santamaria P, Driver JP, Serreze D, Salter MW, Dosch HM (2006) TRPV1+ sensory neurons control beta cell stress and islet inflammation in autoimmune diabetes. Cell 127:1123–1135
187. Engel MA, Khalil M, Mueller-Tribbensee SM, Becker C, Neuhuber WL, Neurath MF, Reeh PW (2012) The proximodistal aggravation of colitis depends on substance P released from TRPV1-expressing sensory neurons. J Gastroenterol 47:256–265
188. Gad M, Pedersen AE, Kristensen NN, Fernandez Cde F, Claesson MH (2009) Blockage of the neurokinin 1 receptor and capsaicin-induced ablation of the enteric afferent nerves protect SCID mice against T-cell-induced chronic colitis. Inflamm Bowel Dis 15:1174–1182
189. Sonea IM, Palmer MV, Akili D, Harp JA (2002) Treatment with neurokinin-1 receptor antagonist reduces severity of inflammatory bowel disease induced by Cryptosporidium parvum. Clin Diagn Lab Immunol 9:333–340
190. Stucchi AF, Shofer S, Leeman S, Materne O, Beer E, McClung J, Shebani K, Moore F, O’Brien M, Becker JM (2000) NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats. Am J Physiol Gastrointest Liver Physiol 279:G1298–G1306
191. Sturiale S, Barbara G, Qiu B, Figini M, Geppetti P, Gerard N, Gerard C, Grady EF, Bunnett NW, Collins SM (1999) Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P. Proc Natl Acad Sci USA 96:11653–11658
192. Ostrowski SM, Belkadi A, Loyd CM, Diaconu D, Ward NL (2011) Cutaneous denervation of psoriasiform mouse skin improves acanthosis and inflammation in a sensory neuropeptide-dependent manner. J Invest Dermatol 131:1530–1538
193. Niizeki H, Kurimoto I, Streilein JW (1999) A substance p agonist acts as an adjuvant to promote hapten-specific skin immunity. J Invest Dermatol 112:437–442
194. Scholzen TE, Steinhoff M, Sindrilaru A, Schwarz A, Bunnett NW, Luger TA, Armstrong CA, Ansel JC (2004) Cutaneous allergic contact dermatitis responses are diminished in mice deficient in neurokinin 1 receptors and augmented by neurokinin 2 receptor blockage. FASEB J 18:1007–1009
195. Elekes K, Helyes Z, Nemeth J, Sandor K, Pozsgai G, Kereskai L, Borzsei R, Pinter E, Szabo A, Szolcsanyi J (2007) Role of capsaicin-sensitive afferents and sensory neuropeptides in endotoxin-induced airway inflammation and consequent bronchial hyperreactivity in the mouse. Regul Pept 141:44–54
196. Joachim RA, Sagach V, Quarcoo D, Dinh T, Arck PC, Klapp BF (2006) Upregulation of tumor necrosis factor-alpha by stress and substance p in a murine model of allergic airway inflammation. Neuroimmunomodulation 13:43–50
197. Ramalho R, Almeida J, Beltrao M, Pirraco A, Costa R, Sokhatska O, Guardao L, Palmares C, Guimaraes JT, Delgado L, Moreira A, Soares R (2013) Substance P antagonist improves both obesity and asthma in a mouse model. Allergy 68:48–54
198. Bang R, Sass G, Kiemer AK, Vollmar AM, Neuhuber WL, Tiegs G (2003) Neurokinin-1 receptor antagonists CP-96,345 and L-733,060 protect mice from cytokine-mediated liver injury. J Pharmacol Exp Ther 305:31–39
199. Hegde A, Zhang H, Moochhala SM, Bhatia M (2007) Neurokinin-1 receptor antagonist treatment protects mice against lung injury in polymicrobial sepsis. J Leukoc Biol 82:678–685
200. Nessler S, Stadelmann C, Bittner A, Schlegel K, Gronen F, Brueck W, Hemmer B, Sommer N (2006) Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist—a putative role for substance P in CNS inflammation. J Neuroimmunol 179:1–8
201. Reinke EK, Johnson MJ, Ling C, Karman J, Lee J, Weinstock JV, Sandor M, Fabry Z (2006) Substance P receptor mediated maintenance of chronic inflammation in EAE. J Neuroimmunol 180:117–125
202. Castagliuolo I, Riegler M, Pasha A, Nikulasson S, Lu B, Gerard C, Gerard NP, Pothoulakis C (1998) Neurokinin-1 (NK-1) receptor is required in Clostridium difficile-induced enteritis. J Clin Invest 101:1547–1550
203. Kincy-Cain T, Bost KL (1996) Increased susceptibility of mice to Salmonella infection following in vivo treatment with the substance P antagonist, spantide II. J Immunol 157:255–264
204. Walters N, Trunkle T, Sura M, Pascual DW (2005) Enhanced immunoglobulin A response and protection against Salmonella enterica serovar typhimurium in the absence of the substance P receptor. Infect Immun 73:317–324
205. McClellan SA, Zhang Y, Barrett RP, Hazlett LD (2008) Substance P promotes susceptibility to Pseudomonas aeruginosa keratitis in resistant mice: anti-inflammatory mediators downregulated. Invest Ophthalmol Vis Sci 49:1502–1511
206. Levite M (1998) Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype. Proc Natl Acad Sci USA 95:12544–12549
207. Grace PM, Hutchinson MR, Maier SF, Watkins LR (2014) Pathological pain and the neuroimmune interface. Nat Rev Immunol 14:217–231
208. Li WW, Guo TZ, Shi X, Sun Y, Wei T, Clark DJ, Kingery WS (2015) Substance P spinal signaling induces glial activation and nociceptive sensitization after fracture. Neuroscience 310:73–90
209. Guo W, Wang H, Watanabe M, Shimizu K, Zou S, LaGraize SC, Wei F, Dubner R, Ren K (2007) Glial–cytokine–neuronal interactions underlying the mechanisms of persistent pain. J Neurosc 27:6006–6018
210. Grace PM, Maier SF, Watkins LR (2015) Opioid-induced central immune signaling: implications for opioid analgesia. Headache 55:475–489
211. Tumati S, Largent-Milnes TM, Keresztes AI, Yamamoto T, Vanderah TW, Roeske WR, Hruby VJ, Varga EV (2012) Tachykinin NK(1) receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation. Eur J Pharmacol 684:64–70
212. Depino AM, Earl C, Kaczmarczyk E, Ferrari C, Besedovsky H, del Rey A, Pitossi FJ, Oertel WH (2003) Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson’s disease. Eur J Neurosci 18:2731–2742
213. McGeer PL, McGeer EG (2008) Glial reactions in Parkinson’s disease. Mov Disord 23:474–483
214. Mosley RL, Benner EJ, Kadiu I, Thomas M, Boska MD, Hasan K, Laurie C, Gendelman HE (2006) Neuroinflammation, oxidative stress and the pathogenesis of Parkinson’s disease. Clin Neurosci Res 6:261–281
215. Thornton E, Vink R (2012) Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson’s disease. PLoS One 7:e34138
216. Lu TS, Avraham HK, Seng S, Tachado SD, Koziel H, Makriyannis A, Avraham S (2008) Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain microvascular endothelial cells. J Immunol 181:6406–6416
217. Lewis KM, Turner RJ, Vink R (2013) Blocking neurogenic inflammation for the treatment of acute disorders of the central nervous system. Int J Inflamm 2013:578480
218. Vink R, van den Heuvel C (2010) Substance P antagonists as a therapeutic approach to improving outcome following traumatic brain injury. Neurotherapeutics 7:74–80
219. Jones MA, Marfurt CF (1998) Peptidergic innervation of the rat cornea. Exp Eye Res 66:421–435
220. Miller A, Costa M, Furness JB, Chubb IW (1981) Substance P immunoreactive sensory nerves supply the rat iris and cornea. Neurosci Lett 23:243–249
221. Brecha NC, Sternini C, Anderson K, Krause JE (1989) Expression and cellular localization of substance P/neurokinin A and neurokinin B mRNAs in the rat retina. Vis Neurosci 3:527–535
222. Fukuda M, Kuwayama Y, Shiosaka S, Ishimoto I, Shimizu Y, Takagi H, Inagaki S, Sakanaka M, Semba E, Takatsuki K, Tohyama M (1981) Demonstration of a substance P-like immunoreactivity in retinal cells of the rat. Neurosci Lett 23:239–242
223. Zhang D, Yeh HH (1992) Substance-P-like immunoreactive amacrine cells in the adult and the developing rat retina. Brain Res Dev Brain Res 68:55–65
224. Lucas K, Karamichos D, Mathew R, Zieske JD, Stein-Streilein J (2012) Retinal laser burn-induced neuropathy leads to substance P-dependent loss of ocular immune privilege. J Immunol 189:1237–1242
225. Hong HS, Kim S, Nam S, Um J, Kim YH, Son Y (2015) Effect of substance P on recovery from laser-induced retinal degeneration. Wound Repair Regen 23:268–277
226. Kubilus JK, Linsenmayer TF (2010) Developmental corneal innervation: interactions between nerves and specialized apical corneal epithelial cells. Invest Ophthalmol Vis Sci 51:782–789
227. Araki-Sasaki K, Aizawa S, Hiramoto M, Nakamura M, Iwase O, Nakata K, Sasaki Y, Mano T, Handa H, Tano Y (2000) Substance P-induced cadherin expression and its signal transduction in a cloned human corneal epithelial cell line. J Cell Physiol 182:189–195
228. Ko JA, Yanai R, Nishida T (2009) Up-regulation of ZO-1 expression and barrier function in cultured human corneal epithelial cells by substance P. FEBS Lett 583:2148–2153
229. Yamada N, Yanai R, Inui M, Nishida T (2005) Sensitizing effect of substance P on corneal epithelial migration induced by IGF-1, fibronectin, or interleukin-6. Invest Ophthalmol Vis Sci 46:833–839
230. Nakamura M, Chikama T, Nishida T (1998) Up-regulation of integrin alpha 5 expression by combination of substance P and insulin-like growth factor-1 in rabbit corneal epithelial cells. Biochem Biophys Res Commun 246:777–782
231. Nakamura M, Nagano T, Chikama T, Nishida T (1998) Up-regulation of phosphorylation of focal adhesion kinase and paxillin by combination of substance P and IGF-1 in SV-40 transformed human corneal epithelial cells. Biochem Biophys Res Commun 242:16–20
232. Brown SM, Lamberts DW, Reid TW, Nishida T, Murphy CJ (1997) Neurotrophic and anhidrotic keratopathy treated with substance P and insulin like growth factor 1. Arch Ophthalmol 115:926–927
233. Chikama T, Fukuda K, Morishige N, Nishida T (1998) Treatment of neurotrophic keratopathy with substance-P-derived peptide (FGLM) and insulin-like growth factor I. Lancet 351:1783–1784
234. Nakamura M, Kawahara M, Morishige N, Chikama T, Nakata K, Nishida T (2003) Promotion of corneal epithelial wound healing in diabetic rats by the combination of a substance P-derived peptide (FGLM-NH2) and insulin-like growth factor-1. Diabetologia 46:839–842
235. Nishida T, Nakamura M, Konma T, Ofuji K, Nagano K, Tanaka T, Enoki M, Reid TW, Brown SM, Murphy CJ, Mannis MJ (1997) Neurotrophic keratopathy—studies on substance P and the clinical significance of corneal sensation. Nihon Ganka Gakkai Zasshi 101:948–974
236. Xu Q, Fitzsimmons B, Steinauer J, O’Neill A, Newton AC, Hua XY, Yaksh TL (2011) Spinal phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling cascades in inflammation-induced hyperalgesia. J Neurosci 31:2113–2124
237. Lighvani S, Huang X, Trivedi PP, Swanborg RH, Hazlett LD (2005) Substance P regulates natural killer cell interferon-gamma production and resistance to Pseudomonas aeruginosa infection. Eur J Immunol 35:1567–1575
238. Cursiefen C (2007) Immune privilege and angiogenic privilege of the cornea. Chem Immunol Allergy 92:50–57
239. Michaels LA, Ohene-Frempong K, Zhao H, Douglas SD (1998) Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis. Blood 92:3148–3151
240. Qazi Y, Hamrah P (2013) Corneal allograft rejection: immunopathogenesis to therapeutics. J Clin Cell Immunol 2013
241. Muller LJ, Marfurt CF, Kruse F, Tervo TM (2003) Corneal nerves: structure, contents and function. Exp Eye Res 76:521–542
242. Rozsa AJ, Beuerman RW (1982) Density and organization of free nerve endings in the corneal epithelium of the rabbit. Pain 14:105–120
243. Benitez del Castillo JM, Wasfy MA, Fernandez C, Garcia-Sanchez J (2004) An in vivo confocal masked study on corneal epithelium and subbasal nerves in patients with dry eye. Invest Ophthalmol Vis Sci 45:3030–3035
244. Benitez-Del-Castillo JM, Acosta MC, Wassfi MA, Diaz-Valle D, Gegundez JA, Fernandez C, Garcia-Sanchez J (2007) Relation between corneal innervation with confocal microscopy and corneal sensitivity with noncontact esthesiometry in patients with dry eye. Invest Ophthalmol Vis Sci 48:173–181
245. Erdelyi B, Kraak R, Zhivov A, Guthoff R, Nemeth J (2007) In vivo confocal laser scanning microscopy of the cornea in dry eye. Graefes Arch Clin Exp Ophthalmol 245:39–44
246. Labbe A, Liang Q, Wang Z, Zhang Y, Xu L, Baudouin C, Sun X (2013) Corneal nerve structure and function in patients with non-sjogren dry eye: clinical correlations. Invest Ophthalmol Vis Sci 54:5144–5150
247. Villani E, Galimberti D, Viola F, Mapelli C, Ratiglia R (2007) The cornea in Sjogren’s syndrome: an in vivo confocal study. Invest Ophthalmol Vis Sci 48:2017–2022
248. Villani E, Magnani F, Viola F, Santaniello A, Scorza R, Nucci P, Ratiglia R (2013) In vivo confocal evaluation of the ocular surface morpho-functional unit in dry eye. Optom Vis Sci 90:576–586
249. Zhang X, Chen Q, Chen W, Cui L, Ma H, Lu F (2011) Tear dynamics and corneal confocal microscopy of subjects with mild self-reported office dry eye. Ophthalmology 118:902–907
250. Shimizu Y (1982) Localization of neuropeptides in the cornea and uvea of the rat: an immunohistochemical study. Cell Mol Biol 28:103–110
251. Tervo K, Tervo T, Eranko L, Eranko O (1981) Substance P immunoreactive nerves in the rodent cornea. Neurosci Lett 25:95–97
252. Stevenson W, Chauhan SK, Dana R (2012) Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol 130:90–100
253. Inomata T, Mashaghi A, Di Zazzo A, Dana R (2015) Ocular surgical models for immune and angiogenic responses. J Biol Methods 2(3):e27